RNTX

Rein Therapeutics, Inc.

Nasdaq· Pharmaceutical Preparations· CIK 0001420565 Biotech & Drug Discovery

$0.5832 +0.00 (+0.21%)

Oct 26 4:00 PM ET · prev $0.5820

Market cap

$52.0M

Micro cap

Consensus

Buy

88% Buy or better · 8 analysts

Median target

🔒 Subscribers only

Next earnings

Nov 12

in 17 days · EPS est. −$0.10

1 year

−56.8%

from $1.35 · Oct 27

30 days

−19.1%

from $0.7210

52-week range

$0.5520–1.88

−69% from high · low Oct 19

Avg volume 20D

469.2K

Oct 15 spike 1.37M

Short interest

651.2K

≈0.8% of shares · −2.9%

Days to cover

2.4

at average volume

Insider net

+$74.6K

2 buyers · 0 sellers · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

SecBot read BULLISH 2 reports · 90 days

Balance 0 bearish · 1 bullish · 1 neutral oldest → newest, height = score

Avg score

·High conf. 1/2 ·Next Earnings date, Nov 12, 2026

Strongest BULLISH Rein Therapeutics reported Q2 2026 GAAP EPS of -$0.10, beating consensus of -$0.27 by 63%, driven by lower…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

B Apr 30 1 insider buy $25.0K at $1.00
R May 1 Rein Therapeutics priced a $50M underwritten public offering of 50M…
R May 4 Rein Therapeutics closed a massively dilutive underwritten public of…
R May 4 Rein Therapeutics is selling 50,000,000 shares (2.8x current outstan…
B May 21 to May 27 4 days of insider buys: $49.6K by 1 insider, avg $1.05
A Jul 20 Maxim Group initiates
R Aug 14 Rein Therapeutics reported Q2 2026 GAAP EPS of -$0.10, beating conse…
E Sep 4 FDA: Rein Therapeutics to Present Late-Breaking Poster at the E…

Signal stack

Where each data set points today.

InsidersBULLISH

2 insiders bought $74.6K at an average $1.03. No open-market sales. Price is 44% below their cost.
InstitutionsBULLISH

Q2 2026: 8 added (0 new), 0 trimmed or exited.
AnalystsBULLISH

7 of 8 rate it Buy or better.
EstimatesRISING

Current-quarter EPS estimate −$0.350 → −$0.100 over 90 days. 1 up, 0 down in 30 days.
Short sellersSTEADY

Short interest −2.9% to 651.2K shares. 2.4 days to cover, ≈0.8% of shares.
TrendDOWNTREND

23% below its 50-day average.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
VANGUARD CAPITAL MANAGEMENT LLC	DOUBLED	3,377,910	$3.5M
GEODE CAPITAL MANAGEMENT, LLC	DOUBLED	733,139	$762.5K
VANGUARD FIDUCIARY TRUST CO	DOUBLED	382,515	$397.8K
STATE STREET CORP	DOUBLED	379,604	$394.8K
BlackRock, Inc.	DOUBLED	326,204	$339.3K
NORTHERN TRUST CORP	DOUBLED	159,720	$166.1K
UBS Group AG	DOUBLED	57,410	$59.7K
MERCER GLOBAL ADVISORS INC /ADV	ADD	50,461	$52.5K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

8 analysts

Buy 88% rate it Buy or better

Strong Buy2Buy5Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access

Recent actions

Date	Firm	Action	Rating
Aug 18, 2026	HC Wainwright & Co. REITERATE	REITERATE	Buy
Jul 20, 2026	Maxim Group INITIATE	INITIATE	Buy
Jun 1, 2026	HC Wainwright & Co. MAINTAIN	MAINTAIN	Buy

Insider ledger

Form 4

$74.6K

bought · 2 insiders

sold · 0 insiders

−43.6%

vs their $1.03 cost

Date	Insider	Type	Value
May 27, 2026	VON RICKENBACH JOSEF H Director	BUY	$4.8K
May 26, 2026	VON RICKENBACH JOSEF H Director	BUY	$24.5K
May 22, 2026	VON RICKENBACH JOSEF H Director	BUY	$16.7K
May 21, 2026	VON RICKENBACH JOSEF H Director	BUY	$3.6K
May 8, 2026	WINDSOR JAMES BRIAN See Remarks	AWARD	150,000 sh
Apr 30, 2026	WINDSOR JAMES BRIAN See Remarks	BUY	$25.0K

Earnings setup

Estimates

Nov 12

reports in 17 days

−$0.10

EPS estimate, this quarter

+71%

estimate change, 90 days

1↑ 0↓

revisions, 30 days

Current-quarter EPS estimate

−$0.350

90d

−$0.100

60d

−$0.100

30d

−$0.090

−$0.100

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.10	-$0.10–-$0.10	+0.0%	$0.00
Next Q	-$0.13	-$0.15–-$0.10	+3.8%	$0.00
Current FY	-$0.46	-$0.47–-$0.45	+13.2%	$0.00
Next FY	-$0.47	-$0.50–-$0.43	+7.0%	$0.00